PROCASPASE 3 ACTIVATION BY COMBINATION THERAPY Russian patent published in 2018 - IPC A61K31/495 A61K31/7048 A61K31/4965 A61K31/282 A61K31/138 A61K31/337 A61K31/404 A61K33/24 A61K47/40 A61P35/00 

FIELD: pharmaceuticals.

SUBSTANCE: group of inventions relates to the chemical-pharmaceutical industry and is a composition for cancer therapy by activating procaspase, containing compound PAC-1:

;

a second active agent selected from: bortezomib, staurosporine, doxorubicin, tamoxifen, cisplatin, carboplatin or paclitaxel; and a pharmaceutically acceptable diluent, excipient and/or carrier, wherein the concentration of PAC-1 is from 2 mcM to 50 mcM, and the concentration of the second active agent is from 1 nM to 1 mM. Also, the invention includes methods for inducing apoptosis in cancer cells and suppressing the growth and/or proliferation of cancer cells for the treatment of cancer by activating procaspase, comprising exposing said cancer cells to an effective amount of the composition described above.

EFFECT: group of inventions provides a synergistic effect of the active agents in the composition, which leads to inducing apoptotic death of cancer cells, and exhibits weaker neurotoxic effects than other compounds and combinations of compounds in this field of medicine.

26 cl, 12 dwg, 1 ex, 3 tbl

РАС-1 - PAC-1